

# *Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin and Non-Hodgkin Lymphoma*

## **TARGET AUDIENCE**

This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

## **OVERVIEW OF ACTIVITY**

Non-Hodgkin lymphoma (NHL) comprises a heterogeneous group of lymphoproliferative disorders and is one of the most rapidly evolving fields in hematology and oncology. In contrast, Hodgkin lymphoma (HL) is a rarer disease that is relatively chemosensitive and often curable when treated appropriately. However, care for patients who do not respond to primary treatment or those with relapsed or refractory HL remains a significant challenge for oncology clinicians. Published results from ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the use of existing treatments. To offer optimal patient care — including the option of clinical trial participation — practicing medical oncologists, hematologists and hematology-oncology fellows must be well informed of these advances. This program uses a roundtable discussion with leading clinical investigators to assist practicing clinicians in formulating up-to-date clinical management strategies for NHL, HL and chronic lymphocytic leukemia (CLL).

## **LEARNING OBJECTIVES**

- Develop an understanding of emerging efficacy and side-effect data with novel agents and combination regimens under evaluation for indolent and aggressive B-cell and T-cell NHL.
- Incorporate new therapeutic strategies into the best-practice management of HL.
- Develop an algorithm for the evaluation and treatment of newly diagnosed and relapsed/refractory CLL.
- Devise an evidence-based approach to the sequential systemic treatment of peripheral T-cell lymphoma.
- Use available research evidence and understand the controversies surrounding the use of CNS prophylaxis to guide treatment decision-making for patients with diffuse large B-cell lymphoma.

## **ACCREDITATION STATEMENT**

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

## **CREDIT DESIGNATION STATEMENT**

Research To Practice designates this enduring material for a maximum of 2.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **HOW TO USE THIS CME ACTIVITY**

This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located at [ResearchToPractice.com/HOUTT113/Video/CME](http://ResearchToPractice.com/HOUTT113/Video/CME).

## **CONTENT VALIDATION AND DISCLOSURES**

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

**FACULTY** — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

### **Andrew M Evens, DO, MSc**

Professor of Medicine  
Chief, Division of Hematology/Oncology  
Tufts University School of Medicine  
Director, Lymphoma Program  
Leader, Clinical Sciences Program  
Tufts Cancer Center  
Boston, Massachusetts

**Advisory Committee:** Millennium: The Takeda Oncology Company, Seattle Genetics, Spectrum Pharmaceuticals Inc;  
**Contracted Research:** Millennium: The Takeda Oncology Company, ZIOPHARM Oncology Inc.

**Christopher Flowers, MD, MS**

Associate Professor of Hematology and Medical Oncology  
Emory School of Medicine  
Winship Cancer Institute  
Atlanta, Georgia

**Consulting Agreements:** Celgene Corporation, Genentech BioOncology; **Contracted Research:** Abbott Laboratories, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Sanofi, Spectrum Pharmaceuticals Inc.

**Jonathan W Friedberg, MD, MMSc**

Samuel Durand Professor of Medicine  
Director, Wilmot Cancer Center  
University of Rochester  
Rochester, New York

**Advisory Committee:** Genentech BioOncology; **Data and Safety Monitoring Board:** Lilly.

**Julie M Vose, MD, MBA**

Neumann M and Mildred E Harris Professor  
Chief, Division of Hematology/Oncology  
Professor of Medicine  
Nebraska Medical Center  
Omaha, Nebraska

**Contracted Research:** Allos Therapeutics, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Incyte Corporation, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals Inc, Pharmacyclics Inc, Sanofi, US Biotest Inc.

**Michael E Williams, MD, ScM**

Byrd S Leavell Professor of Medicine  
Chief, Hematology/Oncology Division  
University of Virginia School of Medicine  
Charlottesville, Virginia

**Advisory Committee:** Celgene Corporation, Genentech BioOncology, Janssen Pharmaceuticals Inc, Onyx Pharmaceuticals Inc; **Consulting Agreements:** Celgene Corporation, Millennium: The Takeda Oncology Company; **Contracted Research:** Allos Therapeutics, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Pharmacyclics Inc.

**MODERATOR** — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

**RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS**

— The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

*This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.*

This activity is supported by educational grants from Genentech BioOncology/Biogen Idec, Lilly, Millennium: The Takeda Oncology Company, Seattle Genetics and Spectrum Pharmaceuticals Inc.

**Hardware/Software Requirements:**

A high-speed Internet connection  
A monitor set to 1280 x 1024 pixels or more  
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later  
Adobe Flash Player 10.2 plug-in or later  
Adobe Acrobat Reader  
(Optional) Sound card and speakers for audio

**Last review date:** November 2013

**Expiration date:** November 2014

## Select Publications

**A randomized, open-label, phase 3 trial of A+AVD versus ABVD as frontline therapy in patients with advanced classical Hodgkin lymphoma. NCT01712490**

Brown JR et al. **Final results of a phase 1 study of idelalisib (GS-1101), a selective inhibitor of phosphatidylinositol 3-kinase p110 delta, in patients with relapsed or refractory CLL. Proc ASCO 2013;Abstract 7003.**

Chen R et al. **Two-year follow-up of patients with relapsed/refractory Hodgkin treated with brentuximab vedotin prior to reduced intensity allogeneic hematopoietic cell transplantation. Proc ICML 2013;Abstract 140.**

Chiappella A et al. **Rituximab-CHOP21 plus lenalidomide is effective and feasible in elderly untreated diffuse large B-cell lymphoma: Results of phase II REAL07 study of the Fondazione Italiana Linfomi (FIL). Proc ASH 2012;Abstract 903.**

**ECOG-E2408: A 3-arm randomized phase II trial of bendamustine-rituximab (BR) followed by rituximab vs bortezomib-BR (BVR) followed by rituximab vs BR followed by lenalidomide/rituximab in high risk follicular lymphoma. NCT01216683**

Friedberg JW et al. **Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol 2013;[Epub ahead of print].**

Goede V et al. **Obinutuzumab (GA101) + chlorambucil (Clb) or rituximab + Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial. Proc ASCO 2013;Abstract 7004.**

Goy A et al. **Single-agent lenalidomide in patients with relapsed/refractory mantle cell lymphoma following bortezomib: Efficacy, safety and pharmacokinetics from the multicenter phase II MCL-001 "EMERGE" trial. Proc EHA 2013;Abstract S1156.**

Kim YH et al. **Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients with CD30-positive cutaneous T-cell lymphoma. The ALCANZA study. Proc ICML 2013;Abstract 572.**

Moskowitz AJ et al. **PET-adapted sequential therapy with brentuximab vedotin and augmented-ICE induces FDG-PET normalization in 92% of patients with relapsed and refractory Hodgkin lymphoma. Proc ICML 2013;Abstract 141.**

Nowakowski GS et al. **Combination of lenalidomide with R-CHOP is well tolerated and effective as initial therapy for aggressive B-cell lymphomas — A phase II study. Proc ASH 2012;Abstract 689.**

O'Brien SM et al. **A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3K $\delta$ ) inhibitor idelalisib (GS-1101) in combination with rituximab in treatment-naïve patients (pts)  $\geq 65$  years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Proc ASCO 2013;Abstract 7005.**

O'Connor OA et al. **Belinostat, a novel pan-histone deacetylase inhibitor in relapsed or refractory peripheral T-cell lymphoma: Results from the BELIEF trial. Proc ASCO 2013;Abstract 8507.**

O'Connor OA et al. **ECHOLON-2: Phase 3 trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients with CD30+ mature T-cell lymphomas. Proc ICML 2013;Abstract 138.**

Press OW et al. **Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol 2013;31(3):314-20.**

**Randomized phase II open label study of lenalidomide R-CHOP (R2CHOP) vs R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) in patients with newly diagnosed diffuse large B cell lymphoma. NCT01856192**

Salles GA et al. **Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: Results from the phase II GAUGUIN study. J Clin Oncol 2013;31(23):2920-6.**

Scholz CW et al. **(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol 2013;31(3):308-13.**

Witzig TE. **Moving radioimmunotherapy forward for follicular lymphoma. J Clin Oncol 2013;31(3):294-6.**

Younes A et al. **Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine versus doxorubicin, bleomycin, vinblastine, and dacarbazine as front-line treatment for advanced classical Hodgkin lymphoma. Proc ASCO 2013;Abstract TPS8612.**